SEATTLE, WA -- (MARKET WIRE) -- May 31, 2007 -- Targeted Genetics Corporation (NASDAQ: TGEN) announced today that its academic collaborators at Columbus Children’s Research Institute (CCRI) and Children’s Hospital of Philadelphia (CHOP) presented data describing a novel cell line-based method for manufacturing AAV-based vaccines. The data are to be presented today in a poster session (Abstract #84) at the 10th Annual Meeting of the American Society of Gene Therapy in Seattle (ASGT). Researchers at Targeted Genetics also presented a poster (Abstract #87) demonstrating the utility of an assay that can be used for testing the stability and relative potency of different lots of AAV-HIV gag based vaccines.
